Literature DB >> 25273930

Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.

Geok-Hoon Lim1, Puay-Hoon Tan, Ana Richelia Jara-Lazaro, Aye Aye Thike, Wey-Cheng Sim, Von-Bing Yap, George Wai-Cheong Yip.   

Abstract

INTRODUCTION: While overexpression of syndecan-1 has been associated with aggressive breast cancer in the Caucasian population, the expression pattern of syndecan-1 in Asian women remains unclear. Triple-positive breast carcinoma, in particular, is a unique subtype that has not been extensively studied. We aimed to evaluate the role of syndecan-1 as a potential biomarker and prognostic factor for triple-positive breast carcinoma in Asian women.
METHODS: Using immunohistochemistry, staining scores of 61 triple‑positive breast carcinoma specimens were correlated with patients' clinicopathological variables such as age, ethnicity, tumour size, histological grade, lymph node status, lymphovascular invasion, associated ductal carcinoma in situ grade, recurrence and overall survival.
RESULTS: Syndecan-1 had intense staining scores in triple‑positive invasive ductal breast carcinomas when compared to normal breast tissue. On multivariate analysis, syndecan-1 epithelial total percentage and immunoreactivity score showed statistical correlation with survival (p = 0.02).
CONCLUSION: The intense staining scores of syndecan-1 and their correlation with overall survival in patients with triple-positive breast carcinoma suggest that syndecan-1 may have a role as a biological and prognostic marker in patients with this specific subtype of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25273930      PMCID: PMC4293941          DOI: 10.11622/smedj.2014115

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  23 in total

1.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility.

Authors:  Ning Yang; Rachel Mosher; Songwon Seo; David Beebe; Andreas Friedl
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.

Authors:  T Maeda; J Desouky; A Friedl
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

4.  Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma.

Authors:  M J Stanley; M W Stanley; R D Sanderson; R Zera
Journal:  Am J Clin Pathol       Date:  1999-09       Impact factor: 2.493

5.  Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.

Authors:  E Tsanou; E Ioachim; E Briasoulis; A Charchanti; K Damala; V Karavasilis; N Pavlidis; N J Agnantis
Journal:  J Exp Clin Cancer Res       Date:  2004-12

6.  Prognostic value of syndecan-1 expression in breast cancer.

Authors:  Marja Leivonen; Johan Lundin; Stig Nordling; Kristina von Boguslawski; Caj Haglund
Journal:  Oncology       Date:  2004       Impact factor: 2.935

7.  Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women.

Authors:  L Lofgren; L Sahlin; S Jiang; B Von Schoultz; R Fernstad; L Skoog; E Von Schoultz
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

8.  High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.

Authors:  Mattia Barbareschi; Patrick Maisonneuve; Daniela Aldovini; Maria Giulia Cangi; Lorenza Pecciarini; Francesco Angelo Mauri; Silvio Veronese; Orazio Caffo; Antonio Lucenti; Paolo Dalla Palma; Enzo Galligioni; Claudio Doglioni
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

9.  An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.

Authors:  Martin Götte; Christian Kersting; Isabel Radke; Ludwig Kiesel; Pia Wülfing
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968-2002.

Authors:  Xueling Sim; R Ayesha Ali; Sara Wedren; Denise Li-Meng Goh; Chuen-Seng Tan; Marie Reilly; Per Hall; Kee-Seng Chia
Journal:  BMC Cancer       Date:  2006-11-02       Impact factor: 4.430

View more
  2 in total

Review 1.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06

2.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.